MOv19 CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes
Term · Oncology and biomedicine · MLC-T-ONC-015292
A preparation of allogeneic CD4-positive and CD8-positive T lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) comprised of an anti-folate receptor alpha (FR-alpha; ovarian tumor-associated antigen MOv18) single chain variable fragment (scFv) (MOv19) and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon administration, MOv19-CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes target, bind to and induce selective toxicity in folate receptor alpha-expressing tumor cells. The costimulatory signaling domain enhances both proliferation of T cells and antitumor activity. Folate receptor alpha is a glycosylphosphatidylinositol-linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, folate receptor alpha expression is limited in normal tissues.
| Identifier | MLC-T-ONC-015292 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-folate receptor alpha-CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes; allogeneic MOv19 CAR-CD3zeta-4-1BB-expressing T lymphocytes; MOv19-CAR-CD3zeta-4-1BB-expressing allogeneic T cells |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015292",
"term": "MOv19 CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes",
"field": "Oncology and biomedicine",
"definition": "A preparation of allogeneic CD4-positive and CD8-positive T lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) comprised of an anti-folate receptor alpha (FR-alpha; ovarian tumor-associated antigen MOv18) single chain variable fragment (scFv) (MOv19) and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon administration, MOv19-CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes target, bind to and induce selective toxicity in folate receptor alpha-expressing tumor cells. The costimulatory signaling domain enhances both proliferation of T cells and antitumor activity. Folate receptor alpha is a glycosylphosphatidylinositol-linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, folate receptor alpha expression is limited in normal tissues.",
"synonyms": [
"anti-folate receptor alpha-CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes",
"allogeneic MOv19 CAR-CD3zeta-4-1BB-expressing T lymphocytes",
"MOv19-CAR-CD3zeta-4-1BB-expressing allogeneic T cells"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/mov19-car-cd3zeta-4-1bb-expressing-allogeneic-t-lymphocytes/"
}
Record 11,299 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.